PHP
GNMK

Parkman Healthcare Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

Parkman Healthcare Partners’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-617,722
Closed -$9.02M – 103
2020
Q4 		$9.02M Buy
617,722
+137,523
+29% +$1.82M 2.31% 13
2020
Q3 		$6.82M Sell
480,199
-319,801
-40% -$4.89M 1.81% 19
2020
Q2 		$11.8M Buy
800,000
+600,000
+300% +$6.1M 3.32% 5
2020
Q1 		$824K Sell
200,000
-220,000
-52% -$1.03M 0.38% 57
2019
Q4 		$2.02M Buy
+420,000
New +$2.32M 0.58% 50

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's GNMK Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 617,722 shares — an estimated $9.02M sold.

Parkman Healthcare Partners first reported a position in GNMK in Q4 2019 and held it in 5 quarters. The position peaked at $11.8M in Q2 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 617,722 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $9.02M.
  • Parkman Healthcare Partners first reported a position in GenMark Diagnostics, Inc in Q4 2019 and held it in 5 quarters.
  • Parkman Healthcare Partners's GenMark Diagnostics, Inc position peaked at $11.8M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.